Sanofi (SNY) is considered one of the best low volatility large cap stocks to invest in, with Deutsche Bank analyst Emmanuel Papadakis maintaining a Buy rating and setting a €110 price target. Sanofi’s Dupixent was approved by the European Commission for the treatment of chronic spontaneous urticaria, making it the first targeted medicine in the EU for this condition in over a decade. The approval was based on phase 3 studies showing a significant reduction in itch and hives with Dupixent. Sanofi specializes in pharmaceutical products across Pharmaceuticals, Consumer Healthcare, and Vaccines segments. While Sanofi shows investment potential, certain AI stocks may offer greater upside with less downside risk.

Read more at Yahoo Finance: Deutsche Bank Maintains a Buy Rating on Sanofi (SNY)